PRMEPrime Medicine, Inc.
$3.58-39% 1Y
$3.58
$2.7052 weeks$6.45
Price
-39%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 6% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for PRME today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$646.6M
1 year-39%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $4.6M (+55% year on year) and net income −$201M. The next results filing is expected around Nov 6, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Jul 8, 2026On July 6, 2026, Prime Medicine, Inc. (the "Company") received a final award (the "Final Award") from the arbitration tribunal (the "Tribunal") in the Company's binding arbitration proceedings with Beam Therapeutics, Inc. ("Beam") regarding the parties' 2019 Collaboration and License Agreement (the "Agreement")Other event · Form 8-K
- May 7, 2026Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.